Prometheus Appoints CTO

Prometheus Biosciences, Inc., a biotechnology company pioneering a precision medicine and companion diagnostics for the treatment of inflammatory bowel disease (IBD), has appointed Olivier Laurent, Ph.D. as Chief Technology Officer. Dr. Laurent will serve on the executive management team and will lead the company's early stage discovery initiatives.

"Dr. Laurent's success in designing and developing biopharmaceuticals products across multiple therapeutic areas, including recombinant proteins and antibodies, is well aligned with our needs as we grow our GI medicines pipeline and our business," said Mark McKenna, President and Chief Executive Officer, Prometheus Biosciences. 

Dr. Laurent most recently served as Chief Scientific Officer at Intrepida Bio, an immuno-oncology company focused on developing novel antibodies for the treatment of solid tumors.  Prior to this position, Dr. Laurent spent twenty years designing and developing biopharmaceuticals at companies including Sanofi, Bayer HealthCare, Genentech, Pfizer, CovX (acquired by Pfizer in 2008) and Ambrx (acquired by a Chinese consortium in 2015). Dr. Laurent holds numerous patents in the field of biotherapeutics and has contributed to multiple antibody regulatory dossiers.